Targeting the nucleus: An overview of auger-electron radionuclide therapy

Current Drug Discovery Technologies

Volumn 7, Issue 4, 2010, Pages 263-279

  Cornelissen, Bart ^a   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Auger electron; Molecular radiotherapy; Nucleus; PRRT; Radioimmunotherapy; Radionuclide; Targeted radiotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 5 IODO 4' THIO 2' DEOXYURIDINE; BLEOMYCIN; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXENDIN 4; GALLIUM 67; IDOXURIDINE; INDIUM 111; IODINE 125; IODINE 131; OCTREOTIDE; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PLATINUM 191; PLATINUM 193M; PLATINUM 195M; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; STEROID; TAMOXIFEN; TECHNETIUM 99M; THALLIUM 201; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DERIVATIVE; VASCULOTROPIN 121; VASCULOTROPIN 165;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER REGRESSION; CANCER SURVIVAL; CELL KILLING; CELL MIGRATION; DNA BINDING; DNA DAMAGE; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE EXPRESSION; HEAD AND NECK TUMOR; HUMAN; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIATION DOSE; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; RADIOISOTOPE THERAPY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE DISTRIBUTION; X IRRADIATION;

ANIMALS; CELL NUCLEUS; CELL SURVIVAL; DNA DAMAGE; DRUG DELIVERY SYSTEMS; ELECTRONS; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 78650770785     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793360657     Document Type: Article

References (260)

1. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4(8): 592-603.
2. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007; 67(19): 8980-4.
3. Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 2010; 17(3): R161-72.
4. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274(5): 420-4.
5. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol 2004; 80(11-12): 789-803.
6. Mariani G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J Nucl Med 2000; 41(9): 1519-21.
7. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996; 41(10): 1973-92.
8. Adelstein SJ. Merrill C. Sosman Lecture. The Auger process: a therapeutic promise? AJR Am J Roentgenol 1993; 160(4): 707-13.
9. Adelstein SJ, Kassis AI. Strand breaks in plasmid DNA following positional changes of Auger-electron-emitting radionuclides. Acta Oncol 1996; 35(7): 797-801.
10. Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapy. Cancer Biother Radiopharm 2003; 18(3): 30116.
11. Bloomer WD, McLaughlin WH, Adelstein SJ, Wolf AP. Therapeutic applications of Auger and alpha emitting radionuclides. Strahlentherapie 1984; 160(12): 755-7.
12. Bodei L, Kassis AI, Adelstein SJ, Mariani G. Radionuclide therapy with iodine-125 and other auger-electron-emitting radionuclides: experimental models and clinical applications. Cancer Biother Radiopharm 2003; 18(6): 861-77.
13. Howell RW. Auger processes in the 21st century. Int J Radiat Biol 2008; 84(12): 959-75.
14. Kassis AI, Fayad F, Kinsey BM, Sastry KS, Taube RA, Adelstein SJ. Radiotoxicity of 125I in mammalian cells. Radiat Res 1987; 111(2): 305-18.
15. Tavares AA, Tavares JM. (99m)Tc Auger electrons for targeted tumour therapy: a review. Int J Radiat Biol 2010; 86(4): 261-70.
16. Wheldon TE, O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radiat Biol 1990; 58(1): 1-21.
17. Woo DV, Li DR, Brady LW, Emrich J, Mattis J, Steplewski Z. Auger electron damage induced by radioiodinated iodine-125 monoclonal antibodies. Front Radiat Ther Oncol 1990; 24: 47-63; discussion 4-8.
18. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005; 46 Suppl 1: 4S-12S.
19. Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006; 33(11): 1352-63.
20. Nikjoo H, Emfietzoglou D, Charlton DE. The Auger effect in physical and biological research. Int J Radiat Biol 2008; 84(12): 1011-26.
21. Nikjoo H, Martin RF, Charlton DE, Terrissol M, Kandaiya S, Lobachevsky P. Modelling of Auger-induced DNA damage by incorporated 125I. Acta Oncol 1996; 35(7): 849-56.
22. Barendswaard EC, Humm JL, O'Donoghue JA, et al. Relative therapeutic efficacy of (125)I-and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med 2001; 42(8): 1251-6.
23. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994; 21(12): 1901-15.
24. Meitner L. Uber die Entstehung der p-Strahl-Spektren radioaktiver Substanzen. Zeitschrift fur Physik A Hadrons and Nuclei 1922; 9(1).
25. Auger P. Sur les rayons p secondaires produits dans un gaz par des rayons X. CRAS 1923; 177: 3.
26. Kassis AI. Cancer therapy with Auger electrons: are we almost there? J Nucl Med 2003; 44(9): 1479-81.
27. Kassis AI. Radiotargeting agents for cancer therapy. Expert Opin Drug Deliv 2005; 2(6): 981-91.
28. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomed 2008; 3(2): 181-99.
29. Boswell CA, Brechbiel MW. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005; 46(12): 1946-7.
30. Adelstein SJ, Kassis AI. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Int J Rad Appl In-strum B 1987; 14(3): 165-9.
31. Kassis AI, Harapanhalli RS, Adelstein SJ. Strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125: direct compared to indirect effects. Radiat Res 1999; 152(5): 530-8.
32. Kassis AI, Harapanhalli RS, Adelstein SJ. Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125. Radiat Res 1999; 151(2): 167-76.
33. Buchegger F, Vieira JM, Blaeuenstein P, et al. Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine. Eur J Nucl Med Mol Imaging 2003; 30(2): 239-46.
34. Behr TM, Behe M, Lohr M, et al. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000; 27(7): 753-65.
35. Behr TM, Sgouros G, Stabin MG, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res 1999; 5(10 Suppl): 3031s-43s.
36. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998; 76(5): 738-48.
37. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003; 66(2): 107-17.
38. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radi-onuclide therapy. Eur J Nucl Med Mol Imaging 2005; 32(11): 1288-95.
39. 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 63(3): 387-94.
40. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36(10): 1902-9.
41. Eckerman K, Endo A, Eds. MIRD: Radionuclide Data and Decay Schemes. 2nd ed. Reston, VA: The Society of Nuclear Medicine 2008.
42. Goddu SM, Howell RW, Rao DV. Calculation of equivalent dose for Auger electron emitting radionuclides distributed in human organs. Acta Oncol 1996; 35(7): 909-16.
43. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994; 35(2): 303-16.
44. Faraggi M, Gardin I, de Labriolle-Vaylet C, Moretti JL, Bok BD. The influence of tracer localization on the electron dose rate delivered to the cell nucleus. J Nucl Med 1994; 35(1): 113-9.
45. Hofer KG. Biophysical aspects of Auger processes. Acta Oncol 2000; 39(6): 651-7.
46. O'Donoghue JA. Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med 1996; 37(4 Suppl): 3S-6S.
47. Kassis AI, Sastry KS, Adelstein SJ. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987; 109(1): 78-89.
48. Makrigiorgos GM, Kassis AI, Baranowska-Kortylewicz J, et al. Radiotoxicity of 5-[123I]iodo-2'-deoxyuridine in V79 cells: a comparison with 5-[125I]iodo-2'-deoxyuridine. Radiat Res 1989; 118(3): 532-44.
49. Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J Pharm Pharmacol 2008; 60(8): 951-8.
50. Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]- octreotide in patients with neuroendocrine tumors. J Nucl Med 2000; 41(9): 1514-8.
51. Reilly RM, Kiarash R, Cameron RG, et al. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000; 41(3): 429-38.
52. Wang J, Chen P, Su ZF, et al. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nucl Med Biol 2001; 28(8): 895-902.
53. Sundberg AL, Almqvist Y, Orlova A, et al. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. Eur J Nucl Med Mol Imaging 2003; 30(10): 1348-56.
54. Bailey KE, Costantini DL, Cai Z, et al. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotox-icity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J Nucl Med 2007; 48(9): 1562-70.
55. McLaughlin WH, Pillai KM, Edasery JP, Blumenthal RD, Bloomer WD. [125I]iodotamoxifen cytotoxicity in cultured human (MCF-7) breast cancer cells. J Steroid Biochem. 1989; 33(4A): 515-9.
56. Salituro FG, Carlson KE, Elliston JF, Katzenellenbogen BS, Katzenellenbogen JA. [125I]iododesethyl tamoxifen aziridine: synthesis and covalent labeling of the estrogen receptor with an iodine-labeled affinity label. Steroids 1986; 48(5-6): 287-313.
57. Hanson RN, Seitz DE, Botarro JC. E-17 al-pha[125I]iodovinylestradiol: an estrogen-receptor-seeking radio-pharmaceutical. J Nucl Med 1982; 23(5): 431-6.
58. Hanson RN, Seitz DE. Tissue distribution of the radiolabeled anti-estrogen [125I]iodotamoxifen. Int J Nucl Med Biol 1982; 9(2): 105-7.
59. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008; 23(1): 3-24.
60. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating pep-tides for in vivo molecular imaging applications. Curr Pharm Des 2008; 14(24): 2415-47.
61. Chen X, Dou S, Liu G, et al. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem 2008; 19(8): 1518-25.
62. Liu X, Wang Y, Nakamura K, Kubo A, Hnatowich DJ. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther 2008; 15(2): 126-32.
63. Watanabe N, Sawai H, Ogihara-Umeda I, et al. Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides. J Nucl Med 2006; 47(10): 1670-7.
64. Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging 2007; 34(3): 368-77.
65. Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991; 21(6): 1541-51.
66. Liu X, Wang Y, Nakamura K, et al. Auger radiation-induced, an-tisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J Nucl Med 2009; 50(4): 582-90.
67. Pouget JP, Santoro L, Raymond L, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res 2008; 170(2): 192-200.
68. Santoro L, Boutaleb S, Garambois V, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmu-notherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009; 50(12): 2033-41.
69. Drecoll E, Gaertner FC, Miederer M, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 2009; 4(5): e5715.
70. Howell RW, Narra VR, Sastry KS, Rao DV. On the equivalent dose for Auger electron emitters. Radiat Res 1993; 134(1): 71-8.
71. Mairs RJ, Fullerton NE, Zalutsky MR, Boyd M. Targeted radiotherapy: microgray doses and the bystander effect. Dose Response 2007; 5(3): 204-13.
72. Boyd M, Ross SC, Dorrens J, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionu-clides. J Nucl Med 2006; 47(6): 1007-15.
73. Chen P, Cameron R, Wang J, Vallis KA, Reilly RM. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 2003; 44(9): 1469-78.
74. Prise KM, Belyakov OV, Newman HC, et al. Non-targeted effects of radiation: bystander responses in cell and tissue models. Radiat Prot Dosimetry 2002; 99(1-4): 223-6.
75. Prise KM, Folkard M, Kuosaite V, Tartier L, Zyuzikov N, Shao C. What role for DNA damage and repair in the bystander response? Mutat Res 2006; 597(1-2): 1-4.
76. Prise KM, Folkard M, Michael BD. Bystander responses induced by low LET radiation. Oncogene 2003; 22(45): 7043-9.
77. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9(5): 351-60.
78. Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002; 99(21): 13765-70.
79. Emerit I. Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 1994; 16(1): 99-109.
80. Bloomer WD, Adelstein SJ. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977; 265(5595): 620-1.
81. Burki HJ, Koch C, Wolff S. Molecular suicide studies of 125I and 3H disintegration in the DNA of Chinese hamster cells. Curr Top Radiat Res Q 1978; 12(1-4): 408-25.
82. Feinendegen LE. Biological damage from the Auger effect, possible benefits. Radiat Environ Biophys 1975; 12(2): 85-99.
83. Krisch RE, Krasin F, Sauri CJ. DNA breakage, repair and lethality after 125I decay in rec+ and recA strains of Escherichia coli. Int J Radiat Biol Relat Stud Phys Chem Med 1976; 29(1): 37-50.
84. Kassis AI, Dahman BA, Adelstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5. Acta Oncol 2000; 39(6): 7317.
85. Daghighian F, Barendswaard E, Welt S, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody. J Nucl Med 1996; 37(6): 1052-7.
86. Mariani G, Cei A, Collecchi P, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following in-tratumoral injection in patients with colorectal cancer. J Nucl Med 1993; 34(7): 1175-83.
87. Reske S, Deisenhofer S, Glatting G, Zlatopolskiy B, Vogg A, Frie-sen C. Auger-electron-DNA-targeted therapy breaks chemo-and radioresistance in leukemia cells. J Nucl Med 2007; 48: 346P.
88. Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radio-labeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002; 43(8): 1072-83.
89. McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Semin Nucl Med 1985; 15(2): 132-53.
90. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77(12): 2061-8.
91. 131I- meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992; 66(6): 1048-52.
92. Mairs RJ, Angerson W, Gaze MN, et al. The distribution of alternative agents for targeted radiotherapy within human neuroblas-toma spheroids. Br J Cancer 1991; 63(3): 404-9.
93. Mairs RJ, Angerson WJ, Babich JW, Murray T. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma. Prog Clin Biol Res 1991; 366: 495-501.
94. 131I]IUdR to human glioma cells in monolayer or spheroid culture: effect of prolifera-tive heterogeneity and radiation cross-fire. Br J Cancer 1998; 77(3): 385-90.
95. Walker KA, Mairs R, Murray T, et al. Tumor spheroid model for the biologically targeted radiotherapy of neuroblastoma microme-tastases. Cancer Res 1990; 50(3 Suppl): 1000s-2s.
96. 131I]-and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Cancer Res 1996; 56(23): 5428-34.
97. He Y, Das B, Baruchel S, Kumar P, Wiebe L, Reilly RM. Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblas-toma cells at concentrations that spare cells of haematopoietic line age. Nucl Med Commun 2004; 25(11): 1125-30.
98. Bloomer WD, McLaughlin WH, Milius RA, Weichselbaum RR, Adelstein SJ. Estrogen receptor-mediated cytotoxicity using iodine-125. J Cell Biochem 1983; 21(1): 39-45.
99. DeSombre ER, Shafii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 1992 15; 52(20): 5752-8.
100. DeSombre ER, Mease RC, Hughes A, Harper PV, DeJesus OT, Friedman AM. Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res 1988; 48(4): 899-906.
101. Bloomer WD, McLaughlin WH, Weichselbaum RR, et al. Iodine-125-labelled tamoxifen is differentially cytoxic to cells containing oestrogen receptors. Int J Radiat Biol Relat Stud Phys Chem Med 1980; 38(2): 197-202.
102. Van de Wiele C, Cocquyt V, VandenBroecke R, et al. Iodine-labeled tamoxifen uptake in primary human breast carcinoma. J Nucl Med 2001; 42(12): 1818-20.
103. Kearney T, Hughes A, Hanson RN, DeSombre ER. Radiotoxicity of Auger electron-emitting estrogens in MCF-7 spheroids: a potential treatment for estrogen receptor-positive tumors. Radiat Res 1999; 151(5): 570-9.
104. Yasui L, Hughes A, DeSombre E. Relative biological effectiveness of accumulated 125IdU and 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells. Radiat Res 2001; 155(2): 328-34.
105. DeSombre ER, Hughes A, Hanson RN, Kearney T. Therapy of estrogen receptor-positive micrometastases in the peritoneal cavity with Auger electron-emitting estrogens--theoretical and practical considerations. Acta Oncol 2000; 39(6): 659-66.
106. DeSombre ER, Hughes A, Landel CC, Greene G, Hanson R, Schwartz JL. Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncol 1996; 35(7): 833-40.
107. Schwartz JL, Mustafi R, Hughes A, DeSombre ER. DNA and chromosome breaks induced by iodine-123-labeled estrogen in Chinese hamster ovary cells. Radiat Res 1996; 146(2): 151-8.
108. Beckmann MW, Scharl A, Rosinsky BJ, Holt JA. Breaks in DNA accompany estrogen-receptor-mediated cytotoxicity from 16 al-pha[125I]iodo-17 beta-estradiol. J Cancer Res Clin Oncol 1993; 119(4): 207-14.
109. Neto C, Oliveira MC, Gano L, et al. Radioiodinated ligands for the estrogen receptor: effect of different 7-cyanoalkyl chains on the binding affinity of novel iodovinyl-6-dehydroestradiols. Appl Ra-diat Isot 2009; 67(2): 301-7.
110. Fischer T, Schomacker K, Schicha H. Diethylstilbestrol (DES) labeled with Auger emitters: potential radiopharmaceutical for therapy of estrogen receptor-positive tumors and their metastases? Int J Radiat Biol 2008; 84(12): 1112-22.
111. Merrick MV, Lavender JP, Poole GW, Stradling P, Thakur ML, Walter LH. 111-In-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen. Br J Radiol 1975; 48(568): 279-85.
112. Thakur ML. The preparation of indium-111 labelled bleomycin for tumour localisation. Int J Appl Radiat Isot 1973; 24(6): 357-9.
113. Kairemo KJ, Ramsay HA, Paavonen TK, et al. Biokinetics of in-dium-111-bleomycin complex in head and neck cancer-implementations for radiochemotherapy. Cancer Detect Prev 1997; 21(1): 83-90.
114. Kairemo KJ, Ramsay HA, Tagesson M, et al. Indium-111 bleomy-cin complex for radiochemotherapy of head and neck cancer--dosimetric and biokinetic aspects. Eur J Nucl Med 1996; 23(6): 631-8.
115. Korppi-Tommola T, Huhmar H, Aronen HJ, et al. 111In-labelled bleomycin complex for the differentiation of high-and low-grade gliomas. Nucl Med Commun 1999; 20(2): 145-52.
116. Ryynanen PM, Savolainen SE, Aronen HJ, et al. Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. Ann Nucl Med 1998; 12(6): 313-21.
117. Hou DY, Maruyama Y. Enhanced killing of human small cell lung cancer by hyperthermia and indium-111-bleomycin complex. J Surg Oncol 1990; 44(1): 5-9.
118. Hou DY, Maruyama Y. Distribution of 111In-bleomycin complex in small cell lung cancer cells by autoradiography. J Surg Oncol 1992; 49(2): 93-7.
119. Hou DY, Maruyama Y, Drago JR. Chromosome aberrations of human small cell lung cancer induced by a new 111In-bleomycin complex. J Surg Oncol 1992; 51(4): 236-42.
120. Hou DY, Hamburger AW, Beach JL, Maruyama Y. Killing of human lung cancer cells using a new [111In]bleomycin complex [111In]BLMC. Cancer Invest 1989;7(6): 543-50.
121. Hou DY, Ordonez JV, Cross RJ, Ross DD, Maruyama Y. Killing lung cancer cells at cell-cycle phase by a new indium-111-bleomycin complex. J Surg Oncol 1989; 40(2): 73-8.
122. Jaaskela-Saari HA, Kairemo KJ, Ramsay HA, Grenman R. Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. Int J Radiat Biol 1998; 73(5): 56570.
123. Hou DY, Hoch H, Johnston GS, et al. A new 111In-bleomycin complex for combined radiotherapy and chemotherapy. J Surg Oncol 1985; 29(2): 91-8.
124. Hou DY, Hoch H, Johnston GS, Tsou KC, Farkas RJ, Miller EE. Use of 111In-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice. J Surg Oncol 1985; 29(2): 71-7.
125. Jaaskela-Saari HA, Grenman R, Ramsay HA, Tarkkanen J, Paa-vonen T, Kairemo KJ. Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice. Cancer Bio-ther Radiopharm 2005; 20(4): 426-35.
126. Hou DY, Hoch H, Johnston GS, et al. A new tumor imaging agent--111In-bleomycin complex. Comparison with 67Ga-citrate and 57Co-bleomycin in tumor-bearing animals. J Surg Oncol 1984; 27(3): 189-95.
127. Hou DY, Hoch H, Johnston GS, et al. A new 111In-bleomycin complex for tumor imaging: preparation, stability, and distribution in glioma-bearing mice. J Surg Oncol 1984; 25(3): 168-75.
128. Hou DY, Hoch H, Johnston GS, Tsou KC, Farkas RJ, Miller EE. Distribution and stability of [111In]bleomycin and its fractions in tumor-bearing mice. Int J Nucl Med Biol 1984; 11(2): 129-39.
129. Howell RW, Sastry S. Cisplatinum-193m: Its microdosimetry and potential for chemo-Auger combination therapy of cancer. Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium. TN, USA 1986.
130. Areberg J, Johnsson A, Wennerberg J. In vitro toxicity of (191 )Pt-labeled cisplatin to a human cervical carcinoma cell line (ME-180). Int J Radiat Oncol Biol Phys 2000; 46(5): 1275-80.
131. Areberg J, Wennerberg J, Johnsson A, Norrgren K, Mattsson S. Antitumor effect of radioactive cisplatin (191Pt) on nude mice. Int J Radiat Oncol Biol Phys 2001; 49(3): 827-32.
132. Ickenstein LM, Edwards K, Sjoberg S, Carlsson J, Gedda L. A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nucl Med Biol 2006; 33(6): 773-83.
133. Fondell A, Edwards K, Ickenstein LM, Sjoberg S, Carlsson J, Gedda L. Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 2010; 37(1): 114-23.
134. Zhang Y, Zhou J, Baldwin J, et al. Ionizing radiation-induced bystander mutagenesis and adaptation: quantitative and temporal aspects. Mutat Res 2009; 671(1-2): 20-5.
135. Cheng M, Huang Y. Nanoparticle-mediated radionuclide-gene therapy of liver cancer. Proceedings of the 2009 World Congress on Medical Physics and Biomedical Engineering, September 7-12, Munich, Germany, 2009.
136. Melis M, Vegt E, Konijnenberg MW, et al. Nephrotoxicity in mice after repeated imaging using 111In-labeled peptides. J Nucl Med 2010; 51(6): 973-7.
137. Vegt E, de Jong M, Wetzels JF, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionu-clide therapy, and strategies for prevention. J Nucl Med 2010; 51(7): 1049-58.
138. Vegt E, Eek A, Oyen WJ, de Jong M, Gotthardt M, Boerman OC. Albumin-derived peptides efficiently reduce renal uptake of radio-labelled peptides. Eur J Nucl Med Mol Imaging 2010; 37(2): 22634.
139. Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007; 48(4): 596-601.
140. Lambert B, Cybulla M, Weiner SM, et al. Renal toxicity after radionuclide therapy. Radiat Res 2004; 161(5): 607-11.
141. de Jong M, Breeman WA, Bernard BF, et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 1999; 26(7): 693-8.
142. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroen-docrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999; 43(4): 356-66.
143. Hofland LJ, Breeman WA, Krenning EP, et al. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Phys 1999; 111(1): 63-9.
144. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003; 63(20): 6864-9.
145. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005; 46(12): 2097-103.
146. Haefliger P, Agorastos N, Renard A, Giambonini-Brugnoli G, Marty C, Alberto R. Cell uptake and radiotoxicity studies of an nuclear localization signal peptide-intercalator conjugate labeled with [99mTc(CO)3]+. Bioconjug Chem 2005; 16(3): 582-7.
147. Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009; 94(11): 4398-405.
148. Gotthardt M, Lalyko G, van Eerd-Vismale J, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 2006; 137(3): 162-7.
149. Wicki A, Wild D, Storch D, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007; 13(12): 3696-705.
150. Wild D, Behe M, Wicki A, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006; 47(12): 2025-33.
151. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharma-ceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010; 51(7): 1059-67.
152. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear trans-localization. Breast Cancer Res Treat 2006; 95(3): 211-8.
153. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3(9): 802-8.
154. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med 2008; 49(8): 1353-61.
155. Cornelissen B, Oltenfreiter R, Kersemans V, et al. In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. Nucl Med Biol 2005; 32(5): 431-6.
156. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007; 48(3): 445-54.
157. Chan C, Cai Z, Su R, Reilly RM. 111In-or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Nucl Med Biol 2010; 37(2): 105-15.
158. Li S, Peck-Radosavljevic M, Koller E, et al. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigra-phy. Int J Cancer 2001; 91(6): 789-96.
159. Li S, Peck-Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003; 14(8): 1274-7.
160. Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 2003; 17(11): 1562-4.
161. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioim-munotherapy. Crit Rev Oncol Hematol 2001; 39(1-2): 195-201.
162. 131I- Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol Apr; 12(2): 198-203.
163. 131I-tositumomab. Semin Oncol 2005; 32(1 Suppl 1): S50-6.
164. Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lym-phoma. Best Pract Res Clin Haematol 2006; 19(4): 655-68.
165. Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res 1989; 49(11): 2952-8.
166. Derui L, Woo DV, Emrich J, et al. Radiotoxicity of 125I-labeled monoclonal antibody 425 against cancer cells containing epidermal growth factor receptor. Am J Clin Oncol 1992; 15(4): 288-94.
167. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 2004; 58(3): 972-5.
168. 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992; 52(1): 121-6.
169. Li L, Quang TS, Gracely EJ, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg 2010; 113(2): 192-8.
170. Chen P, Wang J, Hope K, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 2006; 47(5): 827-36.
171. Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunocon-jugates in tumor-bearing mice following intravenous or intratu-moral injection. Nucl Med Biol 2008; 35(1): 101-10.
172. Kersemans V, Cornelissen B, Minden MD, Brandwein J, Reilly RM. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med 2008; 49(9): 1546-54.
173. Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008; 49(9): 1498-505.
174. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007; 48(8): 1357-68.
175. Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer
176. Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS- trastuzumab. J Nucl Med 2010; 51(3): 477-83.
177. Liang M, Liu X, Cheng D, et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem 2010; 21(7): 1385-8.
178. Wang Y, Liu X, Nakamura K, Chen L, Rusckowski M, Hnatowich DJ. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles. Cancer Biother Radiopharm 2009; 24(5): 573-8.
179. Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M. Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 2004; 45(10): 171620.
180. Karagiannis TC. Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: dual receptor and DNA targeting strategies. Hell J Nucl Med 2007; 10(3): 155-9.
181. Mae M, Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006; 6(5): 509-14.
182. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9(6): 1957-71.
183. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
184. Thisgaard H, Jensen M. 119Sb--a potent Auger emitter for targeted radionuclide therapy. Med Phys 2008; 35(9): 3839-46.
185. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001; 40(5): 602-8.
186. Skarnemark G, Odegaard-Jensen A, Nilsson J, et al. Production of 103mRh for cancer therapy. J Radioanal Nucl Chem 2009; 280(2): 3.
187. Srivastava SC. The Role of Electron-Emitting Radiopharmaceuti-cals in the Palliative Treatment of Metastatic Bone Pain and for Radiosynovectomy: Applications of Conversion Electron Emitter Tin-117m. brazilian archives of biology and technology. 2007; 50.
188. Russell J, O'Donoghue JA, Finn R, et al. Iodination of annexin V for imaging apoptosis. J Nucl Med 2002; 43(5): 671-7.
189. Helisch A, Forster GJ, Reber H, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004; 31(10): 1386-92.
190. Maecke HR. Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop 2005(49): 43-72.
191. Mairs RJ, Wideman CL, Angerson WJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyu-ridine for glioma therapy using a rat model. Br J Cancer 2000; 82(1): 74-80.
192. Vainer E, Faraggi M, Hambright P, Dixon D, Laster B. Localization of InTMPyP for use in Auger Electron Therapy (AET). Proceedings of the 2002 radiation research society annual meeting 2002: P33-321.
193. Baum R, Prasad V, Roether M. Fractionated, low dose/multiple cycles (LD/MT) peptide receptor radionuclide therapy: A new concept for the treatment of well-differentiated metastatic neuroendo-crine tumours. J Nucl Med 2009; 50(S2): S41.
194. Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35(10): 1847-56.
195. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmuno-therapy. Cancer 2002; 94(4 Suppl): 1332-48.
196. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992; 33(9): 1648-53.
197. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose frac-tionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990; 82(9): 763-71.
198. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96(4): 1259-66.
199. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16(10): 3246-56.
200. Denardo GL, Denardo SJ, Kukis DL, et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunother-apy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res 1998; 18(4B): 2779-88.
201. Jones B. Joint symposium 2009 on carbon ion radiotherapy. Br J Radiol 2009; 82(983): 884-9.
202. Jones B, Dale RG. Radiobiologically based assessments of the net costs of fractionated focal radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41(5): 1139-48.
203. Jones B, Dale RG. Mathematical models of tumour and normal tissue response. Acta Oncol 1999; 38(7): 883-93.
204. Tijink BM, Perk LR, Budde M, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009; 36(8): 1235-44.
205. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006; 47(7): 1127-35.
206. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005; 11(11): 1250-5.
207. Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol 2008; 35(6): 673-8.
208. Ruan S, O'Donoghue JA, Larson SM, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med 2000; 41(11): 1905-12.
209. McNally NJ, de Ronde J, Folkard M. Interaction between X-ray and alpha-particle damage in V79 cells. Int J Radiat Biol Relat Stud Phys Chem Med 1988; 53(6): 917-20
210. Bodey RK, Evans PM, Flux GD. Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59(1): 228-41.
211. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 2003; 18(1): 89-97.
212. Burke PA, DeNardo SJ, Miers LA, Kukis DL, DeNardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 2002; 94(4 Suppl): 1320-31.
213. Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. Int J Cancer 2004; 108(2): 293-300.
214. Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmuno-therapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003; 30(5): 777-80.
215. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther 2007; 2(1): 19-31.
216. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24(5): 823-34.
217. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 2006; 24(1): 82-97.
218. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pre-targeting methods. Clin Cancer Res 2005; 11(19 Pt 2): 7109s-21s.
219. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretarget-ing system for cancer detection and therapy using bispecific antibody. Cancer Res 2003; 63(2): 354-63.
220. van Schaijk FG, Oosterwijk E, Soede AC, et al. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re. Clin Cancer Res 2003; 9(10 Pt 2): 3880S-5S.
221. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000; 6(2): 406-14.
222. Lewis MR, Wang M, Axworthy DB, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003; 44(8): 1284-92.
223. Pagel JM, Pantelias A, Hedin N, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lym-phomas. Cancer Res 2007; 67(12): 5921-8.
224. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immu-noscintigraphy, efficacy, and toxicity of conventional and pretar-geted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003; 44(3): 437-45.
225. Shinohara K, Ohara H, Kobayashi K, et al. Enhanced killing of HeLa cells pre-labeled with 5-bromodeoxyuridine by monochromatic synchrotron radiation at 0.9 A: an evidence for Auger enhancement in mammalian cells. J Radiat Res (Tokyo) 1985; 26(3): 334-8.
226. Moiseenko VV, Karnas SJ, Yu E, Battista JJ. Monte Carlo simulations of DNA damage from incorporated cold iodine following photoelectrically induced Auger electron cascades. Radiat Prot Do-simetry 2002; 99(1-4): 113-6.
227. Sun L, Liu D, Wang Z. Functional gold nanoparticle-peptide complexes as cell-targeting agents. Langmuir 2008; 24(18): 10293-7.
228. Pradhan AK, Nahar SN, Montenegro M, et al. Resonant X-ray enhancement of the Auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications. J Phys Chem A 2009; 113(45): 12356-63.
229. Cerullo N, Esposito J, Bufalino D, Mastrullo A, Muzi L, Palmerini S. Preliminary design of a Gd-NCT neutron beam based on compact D-T neutron source. Radiat Prot Dosimetry 2005; 116(1-4 Pt 2): 605-8.
230. Le UM, Shaker DS, Sloat BR, Cui Z. A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Dev Ind Pharm 2008; 34(4): 413-8.
231. Tokumitsu H, Hiratsuka J, Sakurai Y, Kobayashi T, Ichikawa H, Fukumori Y. Gadolinium neutron-capture therapy using novel gadopentetic acid-chitosan complex nanoparticles: in vivo growth suppression of experimental melanoma solid tumor. Cancer Lett 2000; 150(2): 177-82.
232. Urashima T, Nagasawa H, Wang K, Adelstein SJ, Little JB, Kassis AI. Induction of apoptosis in human tumor cells after exposure to Auger electrons: comparison with gamma-ray exposure. Nucl Med Biol 2006; 33(8): 1055-63.
233. Balagurumoorthy P, Chen K, Adelstein SJ, Kassis AI. Auger electron-induced double-strand breaks depend on DNA topology. Ra-diat Res 2008; 170(1): 70-82.
234. Balagurumoorthy P, Wang K, Adelstein SJ, Kassis AI. DNA double-strand breaks induced by decay of (123)I-labeled Hoechst 33342: role of DNA topology. Int J Radiat Biol 2008; 84(12): 97683.
235. Goorley T, Zamenhof R, Nikjoo H. Calculated DNA damage from gadolinium Auger electrons and relation to dose distributions in a head phantom. Int J Radiat Biol 2004; 80(11-12): 933-40.
236. Prise KM, Pinto M, Newman HC, Michael BD. A review of studies of ionizing radiation-induced double-strand break clustering. Ra-diat Res 2001; 156(5 Pt 2): 572-6.
237. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan ra-dioimmunotherapy for relapsed or refractory non-Hodgkin's lym-phoma: combined data from 4 clinical trials. J Nucl Med 2003; 44(3): 465-74.
238. Gokhale AS, Mayadev J, Pohlman B, Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 2005; 63(1): 194-201.
239. Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracel-lular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004; 103(4): 1485-94.
240. Enns L, Bogen KT, Wizniak J, Murtha AD, Weinfeld M. Low-dose radiation hypersensitivity is associated with p53-dependent apopto-sis. Mol Cancer Res 2004; 2(10): 557-66.
241. Mothersill C, Seymour CB. Radiation-induced bystander effectsimplications for cancer. Nat Rev Cancer 2004; 4(2): 158-64.
242. Brans B, Bodei L, Giammarile F, et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007; 34(5): 772-86.
243. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 2010; 54(1): 37-51.
244. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47(9): 1467-75.
245. Thierens HM, Monsieurs MA, Brans B, Van Driessche T, Christi-aens I, Dierckx RA. Dosimetry from organ to cellular dimensions. Comput Med Imaging Graph 2001; 25(2): 187-93.
246. Cai Z, Pignol JP, Chan C, Reilly RM. Cellular dosimetry of (111)In using monte carlo N-particle computer code: comparison with analytic methods and correlation with in vitro cytotoxicity. J Nucl Med 2010; 51(3): 462-70.
247. Charlton DE, Humm JL. A method of calculating initial DNA strand breakage following the decay of incorporated 125I. Int J Ra-diat Biol Relat Stud Phys Chem Med 1988; 53(3): 353-65.
248. Bousis C, Emfietzoglou D, Hadjidoukas P, Nikjoo H. Monte Carlo single-cell dosimetry of Auger-electron emitting radionuclides. Phys Med Biol 2010; 55(9): 2555-72.
249. Ftacnikova S, Bohm R. Monte Carlo Calculations of Energy Deposition in DNA for Auger Emitters. Radiat Prot Dosimetry 2000; 92: 10.
250. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992; 19(6): 1371-83.
251. Humm JL, Charlton DE. A new calculational method to assess the therapeutic potential of Auger electron emission. Int J Radiat Oncol Biol Phys 1989; 17(2): 351-60.
252. Morris JR. More modifiers move on DNA damage. Cancer Res 2010; 70(10): 3861-3.
253. Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 2009; 7(7): 989-99.
254. Carlson DJ, Stewart RD, Semenenko VA, Sandison GA. Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing. Radiat Res 2008; 69(4): 47-59.
255. Semenenko VA, Stewart RD. A fast Monte Carlo algorithm to simulate the spectrum of DNA damages formed by ionizing radiation. Radiat Res 2004; 161(4): 451-7.
256. Semenenko VA, Stewart RD, Ackerman EJ. Monte Carlo simulation of base and nucleotide excision repair of clustered DNA damage sites. I. Model properties and predicted trends. Radiat Res 2005; 164(2): 180-93.
257. Tavares AA, Tavares JM. Evaluating 99mTc Auger electrons for targeted tumor radiotherapy by computational methods. Med Phys 2010; 37(7): 3551.
258. Semenenko VA, Stewart RD. Monte carlo simulation of base and nucleotide excision repair of clustered DNA damage sites. II. Comparisons of model predictions to measured data. Radiat Res 2005; 164(2): 194-201.
259. Emfietzoglou D, Kostarelos K, Hadjidoukas P, et al. Subcellular S-factors for low-energy electrons: a comparison of Monte Carlo simulations and continuous-slowing-down calculations. Int J Radiat Biol 2008; 84(12): 1034-44.
260. Cornelissen B, Darbar S, Sleeth K, Kersemans V, Vallis K. Amplification of IR-induced DNA damage by Auger electron treatment with TAT- radioimmunoconjugates. J Nucl Med 2009; 50(S2): S638.